
GH Stock Forecast & Price Target
GH Analyst Ratings
Bulls say
Guardant Health is well-positioned for long-term success with a growing portfolio of tests, strong customer and payer relationships, and expansion into new markets. Their recent FDA approvals and partnerships with organizations like NCCN and ACS bode well for potential revenue growth. With plans to invest in their Shield screening business, GH has the potential to become a multi-billion dollar company.
Bears say
Guardant Health is facing multiple challenges in the highly competitive and uncertain market of liquid-based cancer tests. While the company has delivered a few positive catalysts in 2026, there remain significant uncertainties and risks in the near term, particularly with regards to Medicare coverage decisions for its Reveal test. Additionally, the company has a high cash burn rate and a smaller market for its blood-based cancer screening test than initially expected. There are also concerns about valuation and competition, and the company may need to raise additional capital in the future. Therefore, the negative outlook on Guardant Health's stock is justified.
This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GH Analyst Forecast & Price Prediction
Start investing in GH
Order type
Buy in
Order amount
Est. shares
0 shares